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IDENTIFICATION OF MESENCHYMAL STEM CELLS AS 
REPLACEMENT CELLS
  Historical studies have shown that bone marrow contains 
non-hematopoietic cells in addition to hematopoietic cells. 
The non-hematopoietic cells adhere to plastic dishes and 
can differentiate into mesenchymal tissues such as osteo-
blasts, chondrocytes, adipocytes, or myoblasts, and are hence 
referred to as mesenchymal stem cells. However, the un-
fractionated mesenchymal cells obtained from bone marrow 
or other tissues are characterized by extensive heterogeneity, 
and cell populations that can satisfy the criteria for being 
stem cells are very rare. Therefore, to clarify the gap between 
nomenclature and function, the International Society for 
Cell Therapy 2005 has adopted the term “mesenchymal 
stromal cells (MSCs)” rather than mesenchymal stem cells. 
  Notably, these plastic-adherent MSCs can be easily cul-
tured in vitro and expanded to a clinical scale. In addition, 
the multilineage differentiation observed in MSCs has en-
abled therapeutic trials to repair various kinds of tissue 
damage using ex vivo-expanded MSCs. These trials included 
cell therapy for regeneration of myocardium in ischemic 
myocardial infarct, regeneration of blood vessels in Buerger’s 
disease, repair of nerve tissues in traumatic injury or ische-
mic cerebral stroke, regeneration of bones in osteogenesis 
imperfecta or in large bone defects, as well as some immuno-
logical applications, such as amelioration of graft-ver-
sus-host disease (Table 1) [1]. While these trials using MSCs 
provided some encouraging results, the extent of functional 
improvement or the contributions of MSCs to the structure 
of the regenerated tissues have not been as satisfactory as 
initially anticipated. For example, while large numbers of 
experimental studies have demonstrated the differentiation 
of MSCs into “myocardium-like cells” expressing myocar-
dium-specific markers, few studies have demonstrated their 
successful differentiation into mature myocardium, or their 
functional integration into the damaged myocardium. 
Similarly, MSCs have been shown to differentiate into vari-
ous types of neuronal tissues but very rarely acquire synaptic 
connections into pre-existing neuronal tissues. Moreover, 
the structural contributions of MSCs as building blocks in 
the regenerated tissues have been limited because of their 
limited survival and the half-life of the transplanted cells. 
Thus, in most trials using MSCs, the major therapeutic bene-
fit does not appear to result from their direct replacement 
of damaged cells. 
NEW UNDERSTANDING OF MSCS AS CELLS FOR RE-
GENERATIVE MICROENVIRONMENT
  While contributions of MSCs by direct differentiation 
into specific types of tissue were limited, MSCs were shown 
to secrete a variety of molecules, including bioactive and 
extracellular matrix factors. Interestingly, the secretion of 
bioactive factors by MSCs was regulated in a manner tightly 
associated with their growth and differentiation, i.e., each 
cellular condition of MSCs gave rise to a distinct set of 
secreted factors. These observations suggested that one of 
the primary and key functions of MSCs is to secrete large 
amounts of bioactive molecules in response to local environ-
mental conditions [2]. Moreover, MSCs have been shown Korean J Hematol 2010;45:219-21.
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Fig. 1. New insights on the in vivo identity of MSCs. MSCs that show
multi-potent differentiation in culture originate from pericytes (or 
skeletal stem cells; SSCs). These SSCs are cellular components in both
the endosteal and perivascular niches as osteoblast or reticular cells 
adjacent to sinus endothelial cells (SECs) that interact with 
hematopoietic stem cells (HSCs) in the bone marrow. Thus, the in vivo
identity of MSCs could be niche cells for tissue-specific stem cells.
Table 1. Representative examples of MSC-based cell therapy trials.
Indication Type of study Results
Myocardial infarct Preclinical/clinical MSCs improved contractility, increase vasculogenesis
Buerger’s disease Clinical MSCs increased capillary formation
Parkinson’s disease Preclinical MSCs migrated to damaged hemispheres in an experimental model
Nerve injury Preclinical MSCs secreted neurotrophin to induce neuronal cell survival and regeneration
Ischemic stroke Clinical MSCs improved the Barthel index and Rankin score
Osteogenesis imperfecta Clinical MSCs increased bone mineral content and growth
Large bone defect Clinical Osteoblasts were grown in scaffolds and repair of bone defectswas improved
Graft-versus-host disease Clinical GVHD was improved in 6/8 patients treated with MSCs
Tumor targeting Preclinical MSCs migrated to tumors and delivered anti-cancer drug
Abbreviations: MSCs, Mesenchymal stromal cells; GVHD, graft-versus-host disease.
to migrate to the site of local tissue injury or inflammation, 
penetrating across the endothelial layers of vessels; this mi-
gration is dependent on the specific interaction of adhesion 
molecules such as P-selectin or VCAM-1 in endothelial 
cells. Taken together, these observations now suggest that 
the therapeutic effects of MSCs may be specific delivery 
of bioactive factors that can facilitate the regeneration of 
tissues at the site of local injury. These effects, termed 
“trophic activity” by A. Caplan [2], exhibit a common mode 
of action of bioactive molecules, i.e., (1) inhibition of apopto-
sis and limitation of the field of damage or injury; (2) in-
hibition of fibrosis or scarring at sites of injury; (3) stim-
ulation of angiogenesis to bring in new blood supply; and 
(4) stimulation of mitosis of tissue-specific and “endogenous” 
stem cells. Other secretary factors include factors for im-
mune modulation to inhibit activation of T-cells, chronic 
inflammatory processes, or autoimmune reactions. Further-
more, MSCs secrete factors that can promote vasculogenesis, 
such as VEGF. Thus, it is possible that the intrinsic function 
of MSCs is not to replace damaged cells but rather to provide 
a regenerative microenvironment. 
  In fact, the hypothesis that MSCs may comprise a re-
generative microenvironment for tissue-specific stem cells 
has been supported by studies on the bone marrow model. 
It was shown that hematopoietic stem cells (HSCs) reside 
in a specialized structure of bone marrow, called niche, 
either in the endosteal or perivasular region. The endosteal 
niche is comprised mainly of osteoblasts in the endosteal 
surface of trabecules, whereas the perivascular niche is com-
prised mainly of reticular cells adjacent to sinus endothelial 
cells (SECs). Notably, recent studies have shown that a spe-
cific population of MSCs that express CD146 can form col-
ony-forming units of fibroblasts (CFU-Fs) and retain the 
potential to regenerate both endosteal and perivascular 
niches. These findings strongly suggest that the cellular 
structures for both types of niches originate from a common 
source, which was referred to as skeletal stem cells (SSCs) 
(Fig. 1) as reviewed by in our previous study [3]. On the 
other hand, a recent study demonstrated that pericytes lo-
cated in the peri-vascular areas of various organs were analo-
gous to MSCs, capable of differentiating into multiple cell 
types such as osteoblasts, adipocytes, and myoblasts. Thus, 
one striking inference about the in vivo identity of MSCs 
is that they may be derived from pericytes, as hypothetically 
illustrated in Fig. 1. Importantly, these pericytes are released 
from vascular structures in the case of focal injury, permit-
ting them to function as repair cells on the site. Altogether, 
it appears that MSCs are an in vivo counterpart of pericytes 
that constitute the stromal structure of the stem cell niche 
for HSCs [3]. Thus, an integrated view of the emerging Korean J Hematol 2010;45:219-21.
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understanding on the role of MSCs might be that MSCs 
function as a local stem cell niche to facilitate the re-
generation of tissue-specific stem cells, rather than function-
ing as replacement cells in the site.
FUTURE DIRECTIONS AND SAFETY CONSIDERATION
  This new insight on MSCs, that they function as a regen-
erative microenvironment, opens an exciting field of future 
studies, specifically the dissection of the cross-talk that may 
occur between the mesenchymal niche cells and tissue-spe-
cific stem cells at the injury site. These interactions between 
the MSC niche and tissue-specific stem cells and their signals 
are now being actively revealed, as reviewed in our recent 
study [4]. Therefore, dissecting the cross-talk in the stem 
cell niche may help identify strategies to coax an optimal 
microenvironment in the tissue, which will then boost the 
use of MSCs in cell therapy. On the other hand, it should 
be also mentioned that safety is the most important factor 
to be considered. While MSCs have been found to be safe 
in most clinical trials, it was shown that the size of ex 
vivo cultured MSCs vary from 15-55 μm in diameter, appa-
rently larger than the pulmonary capillary. Therefore, sev-
eral studies using animal models showed that systemic in-
tra-vasculature injection of MSCs could induce pulmonary 
embolisms in the recipients [5]. In addition, inhibitory ef-
fects of MSCs on immune functions have raised caution 
that MSCs can provoke tumor growth in recipients. Thus, 
additional caution with regard to the safety of MSCs, as 
well as new approaches in their therapeutic use, is necessary 
to ensure therapeutic benefits of MSCs and to overcome 
its intrinsic risk in cell therapeutic trials. Finally, experts 
worldwide are warning against the current trend of medical 
tourism to underdeveloped countries for stem cell injections, 
without sufficient safeguards against possible accidents.
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